New Ordinary Shares

RNS Number : 4572G

Retroscreen Virology Group PLC

04 March 2015

 

For immediate release 07.00: 4 March 2015

RETROSCREEN VIROLOGY GROUP PLC

("Retroscreen" or the "Company")

ISSUE OF ORDINARY SHARES

The Company has issued 438,072 ordinary shares of 5p each ("Ordinary Shares" or the "Issue"), in relation to deferred consideration for the acquisition of Activiomics Limited (233,187 ordinary shares) and an exercise of warrants by Numis Securities Limited (204,885 ordinary shares).  Following the Issue, there are no shares outstanding relating to the deferred consideration of Activiomics Limited and no warrants outstanding exercisable by Numis Securities Limited.

Application has been made for the Ordinary Shares to be admitted to AIM, with trading expected to commence on 9 March 2015 ("Admission").  Upon Admission, the shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

As a result of the Issue, the total number of ordinary shares in issue is 68,097,515, which is the number which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interests in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information please contact:

Retroscreen Virology Group plc                                                            [phone]

Kym Denny (CEO)

Graham Yeatman (FD)

Media Enquiries                                                          [phone] / [phone]

Colin Paterson (Director of Marketing, Communication and Public Relations)

Numis Securities Limited                                                                      [phone]

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

Notes to Editors:

Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing life sciences company based in the UK pioneering a technology platform called hVIVO which uses human models of disease involving healthy volunteers to discover and study new drugs and diagnostics.  To date, Retroscreen has conducted over 35 clinical studies, involving more than 1800 volunteers for a range of leading industry, governmental and academic clients.

 

END

 

 

IOEEAPDDESNSEFF